Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Zhejiang Chinese Medical University | China

Author Profile

Scopus

Biography of Hong-Hong Zhu, MD, MSc, PhD – Professor of Extraordinary Ability 🎓🌍

🎯 Current Role: Leader in Medical Research

Dr. Hong-Hong Zhu is the Head of the Center for Medical Research at Zhejiang Chinese Medical University Affiliated Four-Province-Bordering Hospital of Traditional Chinese Medicine (Quzhou Hospital of TCM). Her leadership in medical research spans over three decades.

📜 Educational Background

  • Ph.D. in Epidemiology from Johns Hopkins University (JHU) Bloomberg School of Public Health (2007)
  • Postdoctoral Training at the U.S. National Institutes of Health (NIH)
  • MD & Master’s Degree in Medicine from Zhejiang University
  • M.Sc. from Clemson University

💡 Key Contributions: Breast Cancer Etiology Pioneer

Dr. Zhu was the first to propose the Synergistic Interaction Theory for breast cancer, linking environmental carcinogens and exogenous hormone use. Her work has significantly advanced the understanding of cancer causes.

🔬 Innovator in Colorectal Cancer Prevention

With 32 years of research in colorectal cancer prevention, Dr. Zhu and her team developed cost-effective screening methods that have saved millions of lives worldwide.

🏆 Academic Achievements and Awards

  • 135 Publications in esteemed journals
  • 35 Awards, including:
    • Best Poster Award (NIH) for breast cancer research (2006)
    • Delta Omega Honor from the U.S. National Public Health Honor Society (2007)
    • Second Place in Scientific Competition in Epidemiology and Public Health (2007)
    • Professor of Extraordinary Ability (2015)
    • Sigma Xi Scientific Research Honor (2024)

📚 Editor and Peer Reviewer

  • Editor-in-Chief of the Journal of GHR (since 2015)
  • Peer Reviewer for academic journals for over 20 years
  • Grant Reviewer for the U.S. Department of Health and Human Services (12 years)

Dr. Hong-Hong Zhu’s contributions to medical research have made her a global figure in epidemiology and cancer prevention.

🔍 Conclusion

With over three decades of research in epidemiology and disease prevention, Dr. Hong-Hong Zhu has made groundbreaking contributions in breast and colorectal cancer research. Her innovative approaches to cancer screening and prevention have been life-saving on a global scale. She remains a recognized leader in public health, continuing to inspire through her research, publications, and numerous honors. 🌟

 

📊🔬NOTABLE PUBLICATION:

 

  • Combining FITs and HRFQ with colonoscopy improve the cost-effectiveness of a 9-year mass colorectal cancer screening program
    Authors: Cai, S.-R., Huang, Y.-Q., Li, Q.-R., Yang, J.-H., Zheng, S.
    Journal: ESMO Open
    Year: 2024

 

  • Sex difference in alcohol consumption associated with colorectal cancer risk in Quzhou, China: A nested case-control study
    Authors: Lai, S.-M., Zhu, H.-H., Gan, Z.-J., Wang, Z.-C., Liao, X.-F.
    Journal: Preventive Medicine Reports
    Year: 2024

 

  • Antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged from 50 to 102 years
    Authors: Zhu, H.-H., Sun, G.-Q., Wu, J.-Y., Wang, Z.-C., Liao, X.-F.
    Journal: Frontiers in Immunology
    Year: 2023

Prof Dr. Tao Sun | Nucleic Acid Drug | Best Researcher Award

Prof Dr. Tao Sun | Nucleic Acid Drug | Best Researcher Award

Nankai University | China

Author Profile

Scopus

Orcid ID

📚 Prof. Tao Sun: Innovator in Oncology and Drug Development

🎓Position:

  • Professor and Doctoral Supervisor, College of Pharmacy, Nankai University, China 🎓

🌟Titles and Awards:

  • National Youth Talent 🌟
  • Winner of the Tianjin Distinguished Youth Scholar 🏆

🔬Research Focus:

  • Molecular mechanisms of malignant tumors 🧬
  • Drug development 💊
  • Pharmacology 🔬

📄Publications:

  • Over 40 papers in prestigious journals, including Advanced Materials, Science Translational Medicine, Hepatology, and Cancer Research, as the first or corresponding author. 📄

📜Patents and Approvals:

  • More than 20 authorized patents 📜
  • 3 new drug clinical approvals ✅

🧪Research Leadership:

  • Principal investigator of 8 major scientific research projects, including Major National Science and Technology Projects and general projects of the National Natural Science Foundation of China. 🧪

🥇Achievements in Education:

  • Instructed students to win the Gold Award in the China International College Students’ “Internet+” Innovation and Entrepreneurship Competition 🥇
  • Recipient of the “Top Ten Award of Scholarly Mentor and Beneficial Friend” at Nankai University 🎖
  • Second Prize winner of the Nankai University Teaching Achievement Award 🥈

💊Summary:

  • Prof. Tao Sun is a distinguished scholar and innovator at Nankai University, renowned for his contributions to oncology, drug development, and pharmacology. His prolific research, numerous patents, and leadership in significant scientific projects underscore his impact in the field. As an educator, he has been instrumental in guiding students to achieve excellence, earning recognition for his mentorship and teaching achievements. 🌟🔬💊

 

📊🔬Notable Publication:

 

Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins

  • Authors: Zhou, B., Zong, S., Zhong, W., … Sun, T., Liu, Y.
    Journal: Oncogene
  • Year: 2020

 

Glycyrrhizic Acid-Induced Differentiation Repressed Stemness in Hepatocellular Carcinoma by Targeting c-Jun N-Terminal Kinase 1

  • Authors: Cai, S., Bi, Z., Bai, Y., … Liu, H., Yang, C.
    Journal: Frontiers in Oncology
  • Year: 2020

 

Twist1-YY1-p300 complex promotes the malignant progression of HCC through activation of miR-9 by forming phase-separated condensates at super-enhancers and relieved by metformin

  • Authors: Meng, J., Han, J., Wang, X., … Liu, H., Sun, T.
    Journal: Pharmacological Research
  • Year: 2023

 

Correction: Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins

  • Authors: Zhou, B., Zong, S., Zhong, W., … Sun, T., Liu, Y.
    Journal: Oncogene
  • Year: 2020

 

YY1 complex promotes quaking expression via super-enhancer binding during EMT of hepatocellular carcinoma

  • Authors: Han, J., Meng, J., Chen, S., … Sun, T., Yang, C.
    Journal: Cancer Research
  • Year: 2019

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • Zitate           4439
  • h-index        35
  • i10-index     49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION: